Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.47 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435092 | 0.99 | PTGS2 (0.53) | PTGS2LMNAACMSDCLCN2SERPINE1 | |
| SCHEMBL4432809 | 0.96 | LMNA (0.50) | PTGS2LMNAACMSDCLCN2SLC6A9 | |
| SCHEMBL17202468 | 0.82 | PTGS2 (0.46) | PTGS2LMNAACMSDGAAMAPT | |
| SCHEMBL1815402 | 0.79 | LMNA (0.47) | LMNA | |
| SCHEMBL23361312 | 0.79 | PTGS2 (0.58) | PTGS2CSF1R | |
| SCHEMBL29826462 | 0.79 | PTGS2 (0.58) | PTGS2CSF1R | |
| SCHEMBL8993514 | 0.74 | PTGS2 (0.52) | PTGS2 | |
| SCHEMBL11580876 | 0.73 | CLCN2 (0.55) | PTGS2ACMSDCLCN2SERPINE1GAA | |
| SCHEMBL7259748 | 0.73 | PTGS2 (0.74) | PTGS2ACMSD | |
| SCHEMBL3875822 | 0.72 | LMNA (0.58) | PTGS2LMNASLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1703909-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | PTGS2 1773/4885LMNA 4830/4885ACMSD 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.